<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-161964</identifier>
<setSpec>1139-6202</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pharmacist intervention in a case of bradycardia by ophtalmic timolol</dc:title>
<dc:description xml:lang="en">A 78-year-old woman who is patient of our community pharmacy asked for our advice. She has been experiencing symptoms such as asthenia, weakness and fatigue for some weeks. The patient was interviewed and main data concerning her pharmacological treatment were collected in an assessment form. Several negative outcomes associated with her medication were detected from which bradycardia was the main matter of concern. A more detailed study of the case revealed that timolol eye drops, which our patient used to treat intraocular hypertension, were systemically absorbed and, thus, may cause adverse cardiovascular effects such as decreased heart rate. Bradycardia may be specially severe in aged persons, in cytochrome P450 CYP2D6 poor metabolizers and in patients taking concomitant enzyme inhibitors. Finally, we issued a report in which we strongly recommend the patient to seek medical advice from her primary care physician in order to find an alternative to timolol treatment. The patient visited the local hospital emergency unit because of an increase on her symptoms. After diagnosing severe bradycardia, a medical emergency team withdrew timolol eyedrops and prescribed an alternative treatment (latanoprost). A few days after our intervention heart rate was normal, initial symptoms were no present and two main negative outcomes associated with her medication had been solved (AU)</dc:description>
<dc:creator>Ramírez López, C</dc:creator>
<dc:creator>Martínez López, LA</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Una paciente habitual de nuestra farmacia comunitaria nos consulta acerca de un cuadro de astenia, debilidad y fatiga de varias semanas de evolución. Tras realizar el estado de situación inicial y estudiar el caso detectamos varios problemas relacionados con medicamentos, siendo una marcada bradicardia el más acuciante. El estudio en detalle de la farmacoterapia de la paciente revela que la fracción de timolol absorbida tras su instilación ocular, que emplea para tratar su hipertensión ocular, podría ser responsable de una acusada disminución de su frecuencia cardiaca. Dicha bradicardia puede ser especialmente significativa en personas de edad avanzada y en individuos que, como consecuencia del polimorfismo de la enzima responsable del metabolismo de timolol, expresan un determinado genotipo con menor capacidad de biotransformación. Intervenimos indicando a la paciente la conveniencia de que su médico valorase otras opciones para el tratamiento de la hipertensión ocular. Tras una visita a urgencias por el agravamiento de los síntomas, se constata la bradicardia severa y el betabloqueante es sustituido por un tratamiento alternativo (latanoprost). La intervención farmacéutica resulta en la retirada de timolol, la remisión de los síntomas y en la resolución de dos problemas relacionados con medicamentos (AU)</dc:description>
<dc:source>Pharm. care Esp;19(2): 93-99, 2017. tab</dc:source>
<dc:identifier>ibc-161964</dc:identifier>
<dc:title xml:lang="es">Intervención farmacéutica en un caso de bradicardia asociada al uso de timolol por vía oftálmica</dc:title>
<dc:subject>^d4418^s22074</dc:subject>
<dc:subject>^d28204^s22057</dc:subject>
<dc:subject>^d14386^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1945^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23169^s22021</dc:subject>
<dc:subject>^d19212</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d10794^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201702</dc:date>
</metadata>
</record>
</ibecs-document>
